| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $954,243 ) |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U01AI165442 | Identification of Metabolic and Immune Deficits in the Aged Population and Their Restoration to Achieve Youthful Anti-Influenza Vaccine Responsiveness | 000 | 5 | NIH | 11/26/2025 | $1,164,461 |
| | 2026 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R35CA242427 | Reading mitochondrial apoptotic signaling to identify active cancer therapeutics | 000 | 7 | NIH | 11/14/2025 | $0 |
| | 2026 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K99CA283154 | Targeting mitochondrial vulnerabilities to drive intrinsic melanoma immunogenicity | 000 | 2 | NIH | 11/19/2025 | $0 |
| | 2026 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | T32CA136432 | Research Training in Pediatric Oncology | 000 | 15 | NIH | 11/21/2025 | -$210,218 |
| | 2026 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA240816 | Characterizing the LINE-1 Retrotransposition-Replication Conflict | 000 | 5 | NIH | 11/25/2025 | $0 |
| | 2026 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | P01AI143565 | Biology and structure of pMHC receptors functioning as mechanosensors in the [alpha][beta] T-cell lineage | 000 | 5 | NIH | 11/17/2025 | $0 |
| | 2026 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01DK124115 | Mitochondria mediated intercellular metabolic coupling in bone marrow regeneration | 000 | 4 | NIH | 11/20/2025 | $0 |
| | 2026 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA237414 | CDK7 inhibitors as a new strategy to overcome treatment resistance in ER+ metastatic breast cancer | 000 | 5 | NIH | 11/21/2025 | $0 |
| | 2026 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | P50CA168504 | Dana-Farber/Harvard Cancer Center SPORE in Breast Cancer | 000 | 10 | NIH | 11/21/2025 | $0 |
| | 2026 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R21CA262991 | Targeting MUC1-C with an antibody drug conjugate for the therapy of advanced prostate cancer | 000 | 1 | NIH | 11/26/2025 | $0 |
| | 2026 | 2019 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U01CA243688 | The AYA-RISE Intervention: Risk Information and Screening Education for Adolescents and Young Adults with Cancer Predisposition Syndromes | 001 | 1 | NIH | 11/20/2025 | -$389,915 |
| | 2026 | 2019 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U01CA243688 | The AYA-RISE Intervention: Risk Information and Screening Education for Adolescents and Young Adults with Cancer Predisposition Syndromes | 000 | 1 | NIH | 11/20/2025 | $389,915 |
|
| Issue Date FY: 2025 ( Subtotal = $171,860,510 ) (Continued on the next page) |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01HL052725 | Molecular Pathogenesis of Fanconi Anemia | 000 | 30 | NIH | 1/8/2025 | $445,000 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U01AI165442 | Identification of Metabolic and Immune Deficits in the Aged Population and Their Restoration to Achieve Youthful Anti-Influenza Vaccine Responsiveness | 000 | 4 | NIH | 11/5/2024 | $1,169,078 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA278980 | Dissecting Convergent Somatic and Germline Alterations that Mediate the Origins and Evolution of Kidney Cancer | 001 | 2 | NIH | 6/6/2025 | $69,113 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA278980 | Dissecting Convergent Somatic and Germline Alterations that Mediate the Origins and Evolution of Kidney Cancer | 000 | 2 | NIH | 11/27/2024 | $622,014 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA279044 | Molecular mechanisms and therapeutic targeting of activated NRF2 signaling in MiT/TFE translocation renal cell carcinoma | 000 | 3 | NIH | 7/10/2025 | $542,189 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K00CA274706 | SIRT1 Regulates RNA Stability to Promote Breast Cancer | 000 | 4 | NIH | 5/13/2025 | $98,626 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R21CA288234 | Investigating Interactions Between Radiation and Antibody-Drug Conjugates in Bladder Cancer | 001 | 2 | NIH | 5/22/2025 | $24,678 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R21CA288234 | Investigating Interactions Between Radiation and Antibody-Drug Conjugates in Bladder Cancer | 000 | 2 | NIH | 2/13/2025 | $222,106 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R00CA286805 | Dissecting the Role of Germline Genetics in RAS-Driven Cancers | 001 | 3 | NIH | 9/22/2025 | -$248,999 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA258688 | Optimizing Therapeutic STING Agonism in Triple Negative Breast Cancer | 001 | 5 | NIH | 5/22/2025 | $40,717 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA258688 | Optimizing Therapeutic STING Agonism in Triple Negative Breast Cancer | 000 | 5 | NIH | 3/13/2025 | $366,458 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R00CA286805 | Dissecting the Role of Germline Genetics in RAS-Driven Cancers | 001 | 3 | NIH | 9/22/2025 | $248,999 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R00CA286805 | Dissecting the Role of Germline Genetics in RAS-Driven Cancers | 000 | 3 | NIH | 8/14/2025 | $248,999 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA248393 | Development of microRNA (miR)-based cell-targeted polymeric nanoparticles for myeloma therapy | 001 | 5 | NIH | 5/22/2025 | $55,087 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA248393 | Development of microRNA (miR)-based cell-targeted polymeric nanoparticles for myeloma therapy | 000 | 5 | NIH | 3/12/2025 | $495,790 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01DE034386 | Dissecting CCL5 contribution to antigen specific T cell responses in head and neck cancers | 000 | 1 | NIH | 8/21/2025 | $3,742,682 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | F32CA284750 | Investigating IGF2BP1 as a novel Therapeutic Target for Ewing Sarcoma | 002 | 2 | NIH | 8/6/2025 | -$54,193 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | F32CA284750 | Investigating IGF2BP1 as a novel Therapeutic Target for Ewing Sarcoma | 001 | 2 | NIH | 5/29/2025 | $1,236 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | F32CA284750 | Investigating IGF2BP1 as a novel Therapeutic Target for Ewing Sarcoma | 000 | 2 | NIH | 3/12/2025 | $74,284 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | F32HL182347 | Examining the role of adenosine-sensing by macrophages in obesity-induced cardiac inflammation | 001 | 1 | NIH | 9/4/2025 | $0 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | F32HL182347 | Examining the role of adenosine-sensing by macrophages in obesity-induced cardiac inflammation | 000 | 1 | NIH | 9/4/2025 | $75,052 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01HG014175 | Calling germline and mosaic variants from long genomic and RNA-seq reads | 000 | 1 | NIH | 8/15/2025 | $501,618 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | F32GM154489 | Expanding the understanding of tRNA lifecycle under cellular stress | 001 | 1 | NIH | 8/29/2025 | $0 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | F32GM154489 | Expanding the understanding of tRNA lifecycle under cellular stress | 000 | 1 | NIH | 8/29/2025 | $78,040 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01LM014775 | Computational methods for multiplex image analysis of the tumor microenvironment | 000 | 1 | NIH | 9/1/2025 | $1,602,000 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K08CA300921 | Immune Evasion through HLA-E in Diffuse Large B-Cell Lymphoma: Defining Its Regulation and Cellular Interactions | 000 | 1 | NIH | 9/2/2025 | $241,884 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | F32CA298459 | Interrogating the role of IFNgamma in promoting metastasis and immune evasion of triple negative breast cancer | 001 | 1 | NIH | 7/15/2025 | $0 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | F32CA298459 | Interrogating the role of IFNgamma in promoting metastasis and immune evasion of triple negative breast cancer | 000 | 1 | NIH | 7/15/2025 | $75,520 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA279391 | Merkel cell polyomavirus HLA class I epitopes for generating therapeutic T cell-based cancer immunotherapy | 001 | 2 | NIH | 5/22/2025 | $70,351 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA279391 | Merkel cell polyomavirus HLA class I epitopes for generating therapeutic T cell-based cancer immunotherapy | 000 | 2 | NIH | 2/13/2025 | $633,159 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K99GM157510 | Revealing Cellular Determinants of LINE-1 Retrotransposition Outcomes | 000 | 1 | NIH | 8/8/2025 | $109,448 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | F31CA301844 | Unraveling the Mechanisms of Neoantigen Vaccine-Induced Epitope Spreading | 000 | 1 | NIH | 6/27/2025 | $36,538 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | F31CA301844 | Unraveling the Mechanisms of Neoantigen Vaccine-Induced Epitope Spreading | 001 | 1 | NIH | 6/27/2025 | $0 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U10CA180794 | ECOG-ACRIN Network Group Statistics and Data Management Center | 001 | 11 | NIH | 7/16/2025 | $3,099,295 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U10CA180794 | ECOG-ACRIN Network Group Statistics and Data Management Center | 000 | 11 | NIH | 2/28/2025 | $4,683,890 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA259273 | Defining epigenetic mechanisms in NPM1c mutant leukemia | 001 | 5 | NIH | 5/22/2025 | $40,361 |
|
